Johnsrud Daniel O, Melduni Rowlens M, Lahr Brian, Yao Xiaoxi, Greason Kevin L, Noseworthy Peter A
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Clin Cardiol. 2018 Dec;41(12):1578-1582. doi: 10.1002/clc.23066. Epub 2018 Dec 10.
Surgical exclusion of the left atrial appendage (LAA) can be performed at the time of cardiac operation as a potential modality to decrease cardioembolic risk attributable to atrial fibrillation (AF), but it remains unclear if this decreases stroke incidence. Furthermore, it is not known whether LAA exclusion impacts the decision to discontinue anticoagulation impacting subsequent stroke risk.
LAA exclusion does not significantly alter subsequent anticoagulation use or stroke incidence.
We studied 124 patients from Olmsted County with prior history of AF who underwent cardiac surgery at our institution between 1993 and 2015. Patients were divided into two groups on the basis of LAA exclusion and matched (1:1) according to 16 pretreatment variables using propensity scores obtained from a logistic regression model. Outcome data collected through chart review for survival, stroke, and the presence and duration of anticoagulation were compared between groups.
The proportion of patients receiving anticoagulation at discharge and at 5 years was not significantly different between patients who underwent LAA exclusion and those who did not; 90% vs 81%, P = 0.156, 48% vs 49%, P = 0.722, respectively. On Kaplan-Meier analysis there were no significant differences in time free from stroke between cases and controls. Patients discharged on oral anticoagulation (OAC) had significantly lower risk of stroke (HR = 0.19, 95% confidence interval [CI] = 0.06-0.59, P = 0.004), independent of whether LAA closure was used.
LAA exclusion did not appear to reduce early or late stroke. Only OAC was associated with a reduction in stroke risk, underscoring the need for continued anticoagulation in high-risk patients.
在心脏手术时可对左心耳(LAA)进行手术切除,作为降低房颤(AF)所致心脏栓塞风险的一种潜在方式,但目前尚不清楚这是否能降低中风发生率。此外,尚不清楚左心耳切除是否会影响停止抗凝治疗的决策,进而影响后续中风风险。
左心耳切除不会显著改变后续抗凝治疗的使用或中风发生率。
我们研究了1993年至2015年间在我们机构接受心脏手术的124名来自奥尔姆斯特德县且有房颤病史的患者。根据左心耳切除情况将患者分为两组,并使用从逻辑回归模型获得的倾向得分,根据16个术前变量进行(1:1)匹配。通过病历审查收集两组患者的生存、中风以及抗凝治疗的使用情况和持续时间等结局数据并进行比较。
接受左心耳切除的患者与未接受左心耳切除的患者在出院时和5年时接受抗凝治疗的比例无显著差异;分别为90%对81%,P = 0.156,48%对49%,P = 0.722。根据Kaplan-Meier分析,病例组和对照组在无中风时间方面无显著差异。口服抗凝药(OAC)出院的患者中风风险显著降低(风险比[HR]=0.19,95%置信区间[CI]=0.06 - 0.59,P = 0.004),与是否使用左心耳闭合术无关。
左心耳切除似乎并未降低早期或晚期中风发生率。只有口服抗凝药与中风风险降低相关,这突出了高危患者持续抗凝治疗的必要性。